New Age Alpha Advisors LLC Purchases Shares of 24,838 Zoetis Inc. (NYSE:ZTS)

New Age Alpha Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,838 shares of the company's stock, valued at approximately $4,047,000.

Other hedge funds have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the last quarter. Dunhill Financial LLC grew its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $44,000. Finally, Asset Planning Inc bought a new stake in Zoetis during the fourth quarter worth $58,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS traded up $1.16 on Wednesday, hitting $163.07. The company's stock had a trading volume of 679,548 shares, compared to its average volume of 2,593,175. The company has a market capitalization of $73.02 billion, a PE ratio of 29.81, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a 50-day simple moving average of $166.26 and a 200 day simple moving average of $174.05. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.23%. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent analyst reports. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target on the stock. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $215.90.

Insider Activity at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 over the last 90 days. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.